Home > ALC>

Prof. Jennifer L. Garst

Duke Raleigh Cancer Center, USA

Email: jennifer.garst@duke.edu


1990 M.D., Medical College of Georgia

1986 B.Sc., University of Georgia

Publications (selected)

  1. Porter LS, Keefe FJ, Davis D, Rumble M, Scipio C, Garst J: Attachment styles in patients with lung cancer and their spouses: associations with patient and spouse adjustment. Support Care Cancer: Jan 13, 2012.
  2. Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. Aug 10; 29(23):3120-5, 2011.
  3. Bastian LA, Fish LJ, Peterson BL, Biddle AK, Garst J, Lyna P, Molner S, Bepler G, Kelley M, Keefe FJ, McBride CM. Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemp Clin Trials. Jul; 32(4):498-504, 2011.
  4. Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE; Cancer, Leukemia Group B Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. Sept; 5(9):1382-90, 2010.
  5. Porter LS, Keefe FJ, Garst J, Baucom DH, McBride CM, McKee DC, Sutton L, Carson K, Knowles V, Rumble M, Scipio C. Caregiver-Assisted Coping Skills Training for Lung Cancer: Results of a Randomized Clinical Trial. J Pain Symptom Manage. Sept 9, 2010.
  6. Ross H, Blumenschein G, Aisner J, Damjanov, N, Dowlati A, Garst J, Rigas J, Smylie M, Hassani H, Allen K, Leopold L, Zaks T, Shepard F: A Randomized Phase II Multicenter Trial Comparing Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Subjects with advanced or Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res: 16; 1938, Mar 2010.
  7. Daniel M, Keefe F, Lyna P, Peterson B, Garst J, Kelley M, Bepler G, Bastian L: Persistent Smoking after a Diagnosis of Lung Cancer is Associate with Higher Reported Pain Levels, J Pain: 10(3): 323–328, 2009.
  8. Jones L, Eves N, Peterson B, Garst J, Crawford J, West M, Mabe S, Harpole D, Kraus W, Douglas P: Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. Cancer: 113(12):3430-9, 2008.
  9. Porter LS, Keefe FJ, Garst J, McBride C, Baucom D, Self-efficacy for Symptom Management in Patients With Lung Cancer and Their Family Caregivers: Associations with Symptoms and Distress. Pain, Jul15; 137(2):306-15, 2008.
  10. Garst J. Topotecan: An Evolving Option for the Treatment of Relapsed Small Cell Lung Cancer. Ther Clin Risk Manag. Dec; 3(6):1087-95, 2007.
  11. Mao J, Kocak Z, Zhou S, Garst J, Evans E, Zhang J, Marks L. The Impact of Induction Chemotherapy and the Associated Tumor Response on Subsequent Radiation-Related Changes in Lung Function and Tumor Response. Int J Radiat Oncol Biol Phys, Feb 2007.
  12. Schiffman SS, Sattely-Miller EA, Taylor EL, Graham BG, Landerman LR, Zervakis J, Cohen HJ, Crawford J, Garst JL. Combination of Flavor Enhancement and Chemosensory Education Improves Nutritional Status in Older Cancer Patients. J Nutr Health Aging. 11(5):439-54, 2007.
  13. Riedel RF, Andrews C, Garst J, Dunphy F, Herndon JE, Blackwell S, Yowell S, Crawford J. A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol, Jun: 2(6):520-525, 2007.
  14. Garst, J. Safety of Topotecan in the Treatment of Recurrent Small-Cell Lung Cancer and Ovarian Cancer. Expert Opinion on Drug Safety, 6(1):53-62, 2007.
  15. Albright C and Garst J. Vaccine Therapy in Non-small Cell Lung Cancer, Curr Onc Reports, 2007.
  16. Riedel RF, Crawford J, Dunphy F, Herndon JE, Padilla K, Garst J, Kelley MJ. Phase II Study of Carboplatin, Irinotecan, and Thalidomide Combination in Patients with Extensive Stage Small-Cell Lung Cancer. Lung Cancer, Dec; 54 (3): 431-432, 2006.
  17. Anscher M, Garst J, Marks L, Larrier N, Dunpy F, Vujaskovic Z, Zhou S, Dewhirst M, Shafman T, Crawford J. Assessing the Ability of the Antiangiogenic and Anticytokine Agent Thalidomide to Modulate Radiation-Induced Lung Injury, Int J Rad Oncol Biol Phys: Aug 10, 2006.
  18. Garst J, Herndon J, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Eaborn E, Anderson E, Johnston E, Crawford J. A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Chemotherapy for the Treatment of Small Cell Lung Cancer. Clinical Drug Investigation 26 (5): 257-66, 2006.
  19. Coscio AM, Garst, J. Lung Cancer in Women. Current Oncology Reports 8:248-251, 2006.
  20. Garst J, Whittington E. A Waste of Taste: Taste Alterations During Cancer Therapy Can Make Food Unenjoyable. Cure: 5(4), 2006.